<DOC>
	<DOCNO>NCT01473953</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial investigate safety , tolerability pharmacokinetics ( exposure body ) liraglutide-depot healthy subject .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Liraglutide-depot Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Body mass index ( BMI ) 20 35 kg/m^2 ( inclusive ) body weight least 60 kg Apart obese ( BMI 30 kg/m^2 ) subject consider generally healthy Medical history , presence , cancer , diabetes clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrine , haematological , dermatological , venereal , neurological , psychiatric disease major disorder Clinical laboratory finding suggest subject consider generally healthy Prescription medicine nonprescription medicine exception Current prior history alcohol drug abuse Current smoking 5 cigarette per day Mental incapacity , language barrier , unwillingness comply protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>